A drug used to suppress the immune system before hematopoietic cell transplant and for treating some cancers.
« Back to Glossary IndexNews
Related News
Join Lori Krause for a workshop designed to explore and process “living losses”—non-death-related losses that arise from life transitions, changes, or unmet expectations. Examples of living losses include the loss of identity, health, relationships, careers, or abilities. Participants will gain tools...
Institution: Laboratorio de Citogenetica, Instituto Nacional de Pediatría, Mexico City, México Area of expertise: Medical genetics, dysmorphology. My work: I am a medical geneticist from Mexico City, introduced to the field of Fanconi anemia (FA) by my mentor, Dr. Sara Frias, whom...
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.